Immune checkpoint Inhibitor drugs blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. There are two main immune checkpoint molecules, cytotoxic T‑lymphocyte protein 4 (CTLA4) and programmed cell-death protein 1 (PD1), that negatively regulates cytotoxic T‑cell activation. Three immune checkpoint inhibitors for the treatment of malignant melanoma and currently available in the market includes ipilimumab (Yervoy), nivolumab (Opdivo), and pembrolizumab (Keytruda). In 2011, US Food and Drug Administration (FDA) approved ipilimumab, monoclonal CTLA4-specific antibody, while pembrolizumab, a PD1-specific monoclonal antibody gained accelerated FDA approval for advanced and unresectable malignant melanoma in 2014, and nivolumab, an anti-PD1 and BRAF inhibitor was granted breakthrough therapy designation (BTD) status in 2015. A number of drug combinations that include checkpoint inhibitors are in clinical development. Cancer survival rates are generally increasing in the United States. These trends have been partially attributed to improvement in therapeutic strategies. The early success of immune checkpoint inhibitors in solid tumors and cancer immunotherapies in general has generated a tremendous interest in further developing and exploring these strategies across the oncology disease spectrum.
The global immune checkpoint inhibitors market segmentation is based on drug type (brand) – atezolizumab (Tecentriq, MPDL3280A), durvalumab (Imfinzi, MEDI4736), ipilimumab (Yervoy), nivolumab (Opdivo), and pembrolizumab (Keytruda).
The global immune checkpoint inhibitors market research report provides market size (Revenue US$ Million 2014 to 2025), market share analysis, growth trends and forecast (CAGR%, 2017 to 2025). The global immune checkpoint inhibitors market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global immune checkpoint inhibitors market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global immune checkpoint inhibitors market and profiled in this report include AstraZeneca, Bristol-Myers Squibb, CureTech Ltd., Incyte, Medimmune, Merck & Co., NewLink Genetics, Ono Pharmaceuticals, Pfizer, and Roche (Genentech).